[A18-41] Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2018
Commission awarded on 21.06.2018 by the Federal Joint Committee (G-BA).
Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence, in combination with trastuzumab and chemotherapy
Patients < 65 years: added benefit not proven; patients ≥ 65 years: hint of lesser benefit in comparison with the appropriate comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A13-28||Addendum to Commission A13-10 (pertuzumab)||Commission completed|
|A16-01||Pertuzumab - Addendum to Commission A15-34||Commission completed|
|A13-10||Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|
|A15-34||Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)||Commission completed|
|A18-76||Pertuzumab (breast cancer) - Addendum to Commission A18-41||Commission completed|